NAFDAC Good Manufacturing Practice for Pharmaceutical Products Guidelines 2024 — Audit-Readiness Rubric — Regscribe v0

(National Agency for Food and Drug Administration and Control — Drug Evaluation & Research (DER) Directorate, Doc. Ref. No. DER-GDL-019-03)

Scope boundary — read this before scoring anything. NAFDAC regulates food, drugs, cosmetics, medical devices, chemicals, and detergents under one statute, but issues separate GMP instruments per product category. This rubric covers only:

• NAFDAC GMP for Pharmaceutical Products Guidelines 2024 (Doc. Ref. No. DER-GDL-019-03, effective 26 November 2024, review date 25 November 2029) — this document. Covers finished human/animal pharmaceutical products (and, per its own stated scope, biological and veterinary products, plus pharmaceutical manufacturing undertaken in hospitals). Structured in 11 chapters: Pharmaceutical Quality System, Personnel, Premises and Equipment, Qualification and Validation, Documentation, Production, Materials Management, Quality Control, Contract Manufacturing and Analysis, Complaints and Product Recall, Self-Inspection.

Explicitly out of scope for this rubric, each a separate NAFDAC instrument not researched to rubric-depth this session:

• NAFDAC GMP Guidelines for Active Pharmaceutical Ingredients (APIs), 2025 Revised (effective 18 June 2025) — adopts ICH Q7 for API manufacturers specifically. A pharmaceutical company that both synthesizes its own API and formulates finished product needs both this rubric and the API-specific guideline; this rubric's Chapter 7 (Materials Management) rows below cover the finished-product manufacturer's incoming-API-testing/supplier-qualification obligations, not the API manufacturer's own ICH-Q7-equivalent GMP obligations.
• NAFDAC Good Manufacturing Practice for Medical Devices and Related Products Regulations 2024 (draft, per filename found) — devices, not drugs.
• NAFDAC Good Manufacturing Practice for Food Regulations 2019 — food, not drugs; a structurally similar but legally distinct instrument issued under the same NAFDAC Act.
• Guidelines For Contract Manufacturing Of Finished Pharmaceutical Products In Nigeria (Doc. Ref. No. DER-GDL-023-00) — the 2024 GMP Guidelines' own Chapter 9 explicitly defers detail to this separate document, which was not independently fetched this session. Treat Chapter 9 rows below as a summary only.
• NAFDAC Inspector's Guide to GMP Inspection of Manufacturing Sites (2023) and Guidelines for Pre-Registration Inspection of Pharm Facilities — inspection-procedure documents (how NAFDAC inspects), not GMP substantive requirements themselves; useful future context for Regscribe's severity-weighting but not mined for clause content this session.

Legal basis (verified from the primary document itself): the Guidelines' own Introduction states NAFDAC's regulatory mandate derives from the NAFDAC Act, Cap N1, Laws of the Federation of Nigeria (LFN) 2004, and that the Agency "has developed NAFDAC Good Manufacturing Practice Regulations which stipulate the minimum standards" — with the 2024 Guidelines document positioned as implementation guidance for those Regulations, not the binding legal instrument itself. This rubric could not confirm the current in-force status of a finalized, gazetted "NAFDAC Good Manufacturing Practice for Pharmaceutical Products Regulations." The only document found under that title (fetched and text-extracted this session) is dated 2019 and is explicitly marked as a public-comment draft ("Comments are welcomed from stakeholders within 60 calendar days, ending 2nd September, 2019"), citing authority under NAFDAC Act ss. 5 and 30 plus Food, Drug and Related Products (Registration, Etc.) Act Cap F33 LFN 2004. Its 18-part structure (Scope, Applicability, Prohibition, then chapters mirroring the 2024 Guidelines' own 11 chapters, then Non-compliance, Penalty, Interpretations, Citation) matches the Guidelines' chapter structure almost exactly, strongly suggesting it is the parent Regulations the 2024 Guidelines refer to — but whether this specific 2019 draft was ever finalized/gazetted, or superseded by a later draft, was not confirmed this session. This rubric therefore cites the 2024 Guidelines' own clause numbers throughout (the document actually in force and used for compliance guidance, per NAFDAC's own site), and flags the underlying Regulations' legal-force status as unverified — see Gaps.

PIC/S status (verified via WebFetch of picscheme.org, dated 30 September 2025 — do not assume full/associate membership): Nigeria is not a PIC/S member or associate member. NAFDAC and the Pharmacy Council of Nigeria jointly submitted a pre-accession application on 8 May 2025; a Rapporteur was appointed by written procedure on 15 August 2025, which PIC/S states "marks the start of the pre-accession process." As of the most recent source found (September 2025), Nigeria's status is PIC/S pre-applicant — an early-stage administrative step, with no completion timeline stated. The 2024 Guidelines' own Introduction states the document "is to be used in conjunction with... all current WHO GMP guidelines and annexures, as well as other related International Guidelines such as PIC/S, ICH, EMA etc" — meaning NAFDAC treats PIC/S materials as an interpretive/informal reference, similar in spirit to (but with far less formal standing than) Japan's post-2014-PIC/S-membership use of the PIC/S Guide. Do not describe NAFDAC as "PIC/S-aligned" or "on track for PIC/S membership" in any Regscribe-facing copy without this pre-applicant caveat attached.

Sources used

Regulatory text (primary — structure, clause numbers, clause text):

• NAFDAC GMP for Pharmaceutical Products Guidelines 2024 — fetched directly from nafdac.gov.ng/wp-content/uploads/Files/Resources/Guidelines/DRUG_GUIDELINES/NAFDAC-GMP-GUIDELINES.pdf (116 pages). This PDF has a genuine text layer (not scanned images) and was cleanly extracted via pdftotext -layout after an initial WebFetch attempt returned only raw binary/stream data — the full text (4,757 lines) was read directly from the extracted file. This is the single primary source underlying every clause citation and clause-text paraphrase below. Doc. Ref. No. DER-GDL-019-03; Effective Date 26 November 2024; Review Date 25 November 2029 (both stated on every page header of the source PDF).
• Known defect in the source document's own clause numbering, confirmed by direct inspection: Chapter 3 ("Premises and Equipment") does not reset its clause numbering to a "3.x" series — it continues the prior chapter's "2.x" numbering all the way through (observed running from 2.33 to at least 2.123 before Chapter 4 begins its own correctly-reset "4.1" series). This was confirmed by grep-checking every numbered clause in the extracted text, not a single stray typo — the entire chapter is affected. This is a defect in NAFDAC's own published PDF, not a transcription error introduced in this rubric. Citations below for Chapter 3 rows use the clause numbers exactly as printed in the source (i.e., "cl. 2.4x" under the "Chapter 3" heading), with this quirk flagged inline so a future reader isn't confused into thinking this rubric misfiled a Chapter 2 clause under Chapter 3.
• NAFDAC's own References section (page 110 of the source PDF) cites, verbatim: EudraLex Volume 4 (EU GMP); WHO Technical Report Series No. 961 (2011) "Good Manufacturing Practices for Pharmaceutical Products"; Health Canada GUI-0001 (2009 ed., v2, 2011); WHO TRS No. 996 (2016), Annex 5, "Guidance on Good Data and Record Management Practices"; and the PIC/S "Guide to good manufacturing practice for medicinal plants" (March 2014). Independently cross-checking the Guidelines' clause text against WHO TRS 961 and EU GMP Vol. 4 Chapter 1 (already fetched for the companion gmp-gdp-rubric.md) confirms the NAFDAC document's Chapter 1 (Pharmaceutical Quality System) and Chapter 2 (Personnel) text is, in substantial stretches, near-verbatim reproduction of WHO TRS 961's own GMP main text — this is disclosed transparently by NAFDAC's own References section (it names WHO TRS 961 as a source) rather than being a hidden plagiarism concern; it means clause-level cross-referencing to the WHO GMP main text (not separately rubric'd in this project) would be unusually clean if ever needed, and that much of this rubric's "Common failure pattern" reasoning for Ch.1/Ch.2 rows can safely reuse patterns already documented in the companion gmp-gdp-rubric.md for the equivalent EU GMP Ch.1 clauses, since the underlying text is closely related.
• NAFDAC GMP Regulations legal-force status: see the "Legal basis" note above — flagged as [UNVERIFIED — flagged, not used] for the specific claim that a finalized/gazetted Regulations instrument (as opposed to the 2024 Guidelines implementing it) is currently in force; the only version found was a 2019 public-comment draft, fetched from nafdac.gov.ng/wp-content/uploads/Files/Resources/Regulations/DRAFT_REGULATIONS/Good-Manufacturing-Practice-For-Pharmaceutical-Products-Regulations.pdf and text-extracted via pdftotext.
• PIC/S pre-applicant status: confirmed via WebFetch of picscheme.org/en/news/nigeria-tanzania-rwanda-and-senegal-become-pics-pre-applican (dated 30 September 2025) — a primary PIC/S Secretariat announcement, not a secondary summary.

Enforcement / failure-pattern data — the counterfeit-vs-GMP-gap distinction is the single most important sourcing judgment call in this document:

• "My Pikin" / Barewa Pharmaceuticals Ltd., Lagos (November 2008 – 2009) — the best-documented case found this session, and the one this rubric relies on most heavily. Multiple independent, mutually consistent contemporaneous sources (CNN, 18 Dec 2008; NBC News; Partnership for Safe Medicines; a peer-reviewed case series in Pediatric Nephrology, Springer, on diagnosing the resulting renal failure in affected children) confirm: Barewa Pharmaceuticals — a Lagos-based, NAFDAC-registered manufacturer, not a counterfeit or unlicensed operation — produced "My Pikin" teething mixture using a batch of propylene glycol (a normal, permitted excipient) that had in fact been substituted, at the raw-material-procurement stage, with diethylene glycol (DEG), a toxic industrial solvent. Per Partnership for Safe Medicines' account, a company official sourced the material from an unregistered chemical dealer, receiving roughly 10 gallons in an unsealed, unlabeled plastic container. At least 84 children died (some contemporaneous reports cite up to ~111 affected); NAFDAC shut the facility down on 26 November 2008; 12 people were arrested including Barewa officials. Categorization (load-bearing for this rubric's central instruction): this is a licensed manufacturer's Good Manufacturing Practice failure — specifically, a Materials Management (Chapter 7) failure to qualify the supplier and to test the incoming material for identity before use — not a counterfeit-supply-chain case. The finished product itself was not counterfeit; the failure was that a genuine, registered manufacturer's incoming-raw-material control broke down. Marked [HISTORICAL] below, used specifically against the Chapter 7 supplier-approval and incoming-identity-testing rows, where it is a close-to-perfect illustration of exactly the failure mode those clauses exist to prevent.
• EuroPharm Laboratories / Eurolink Nigeria Ltd., Jos (NAFDAC Public Alert No. 040/2025, 2 December 2025) — a genuinely current, NAFDAC-primary-sourced case, fetched directly from nafdac.gov.ng. NAFDAC's own alert states the facility "has been producing, selling, and distributing multiple pharmaceutical and other regulated products without the necessary marketing authorization (MA)," and that laboratory analysis of two products (Linmoxyn Amoxicillin oral suspension and Linmoxyn Amoxicillin 500mg capsules) found active-ingredient content of 13.9–18.4% and 48.3% respectively against label claim — i.e., substantially substandard, not merely off-spec. Categorization: this is neither a "licensed facility with a GMP gap" case nor classic brand counterfeiting — it is an unlicensed/unregistered manufacturing operation. It is included, marked [ANALOGOUS], only as illustrative of what undetected substandard API content looks like in practice (relevant to this rubric's Chapter 8 Quality Control / assay-testing rows), with the explicit caveat that the underlying company itself was operating outside the marketing-authorization system this GMP rubric assumes as a starting condition — Regscribe should not present this case as "a NAFDAC-registered GMP-compliant facility failed an inspection," because that is not what NAFDAC's own alert says happened.
• Benylin Paediatric Syrup recall (April 2024) — widely reported (SAHPRA, Kenvue/za.kenvuebrands.com, Daily Maverick, IOL, TimesLive) and directly involves NAFDAC as the triggering regulator: NAFDAC's own testing flagged elevated diethylene glycol in two batches, which NAFDAC reported to South Africa's SAHPRA on 10 April 2024, leading to a multi-country recall (South Africa, Eswatini, Rwanda, Kenya, Tanzania, Nigeria). Two important caveats, both load-bearing: (1) the manufacturing site was in South Africa (Kenvue, formerly Johnson & Johnson) — this is a SAHPRA-jurisdiction GMP matter, not a NAFDAC-jurisdiction manufacturing-site finding, even though NAFDAC's surveillance triggered it; and (2) the underlying contamination finding was subsequently disputed — SAHPRA's own independent retesting and Kenvue's retesting, both using the WHO-recommended method, found no detectable DEG/EG in the batches, and SAHPRA cleared the product in June 2024. This case is retained, marked [ANALOGOUS] and flagged as disputed/unresolved, purely to illustrate NAFDAC's Chapter 10 (Complaints and Product Recall) surveillance-and-notification mechanism functioning in practice — it should not be cited anywhere as a confirmed GMP violation, by NAFDAC or by anyone else, since the best available evidence is that the contamination claim did not hold up.
• No NAFDAC-published, English-language, aggregate GMP inspection-deficiency dataset (i.e., nothing analogous to MHRA's published deficiency-trend reports used in the companion gmp-gdp-rubric.md) was found this session. Every failure-pattern cell below is therefore either a named case (with the categorization caveats above) or a structural/interpretive inference from the Guidelines' own text and its close textual relationship to WHO TRS 961/EU GMP — no clause below should be treated as empirically frequency-weighted the way several rows in the companion EU rubric are.
• Widespread, well-documented counterfeit/substandard-medicine problem in Nigeria generally (WHO estimates, NAFDAC's own recurrent public alerts, extensive academic literature on Nigeria's pharmaceutical supply chain) was not separately mined for named cases this session, beyond the three above — deliberately, because counterfeit-supply-chain enforcement (NAFDAC's anti-counterfeiting/import-control mandate) is a different regulatory function from GMP gap-analysis of a facility's own compliance documentation, which is this rubric's and Regscribe's actual purpose. Folding generic counterfeiting statistics into this rubric would have been exactly the kind of category conflation this project's sourcing rules are designed to prevent.

Rubric legend

Each row: Requirement (plain language) → Citation → Evidence that demonstrates compliance → Common failure pattern

Failure-pattern cells are marked:

• [HISTORICAL] — a real, confirmed, publicly-documented case involving a licensed/registered Nigerian manufacturer, used to illustrate why a specific clause exists. Reserved in this document for the Barewa Pharmaceuticals / "My Pikin" case, which is the only case found this session meeting the "licensed facility, genuine GMP-relevant gap, not counterfeiting" test the task requires.
• [REPRESENTATIVE] — a well-established, textbook-level GMP failure mode, grounded in the Guidelines' own text and/or its close structural relationship to WHO TRS 961 / EU GMP Vol. 4 (whose MHRA-documented failure patterns, in the companion gmp-gdp-rubric.md, are substantively transferable given the near-identical underlying clause text) — not tied to a NAFDAC-specific named enforcement action verified this session.
• [ANALOGOUS] — a real, confirmed, publicly-documented case that is instructive but falls outside the precise "licensed facility, confirmed GMP gap" category this rubric targets — either because the facility was unlicensed (EuroPharm/Eurolink), because the manufacturing site was outside NAFDAC's jurisdiction and the underlying contamination claim was subsequently disputed (Benylin), or both. Included only with the caveat stated inline, never as confirmed NAFDAC GMP-inspection precedent.
• [UNVERIFIED — flagged, not used] — a claim that could not be independently verified this session and is therefore not used to support any requirement row below (used above for the underlying Regulations' gazettal status).

CHAPTER 1 — Pharmaceutical Quality System

CHAPTER 2 — Personnel

CHAPTER 3 — Premises and Equipment

(Note the source document's own clause-numbering defect flagged in Sources above: this entire chapter continues the prior chapter's "2.x" numbering rather than resetting to "3.x" — citations below reproduce the numbers exactly as printed.)

CHAPTER 4 — Qualification and Validation

CHAPTER 5 — Documentation

CHAPTER 6 — Production

CHAPTER 7 — Materials Management

CHAPTER 8 — Quality Control

CHAPTER 9 — Contract Manufacturing and Analysis

(This chapter is deliberately brief in the source document, which explicitly defers detail to a separate guidance document — see Sources above. Treat these two rows as a floor, not a ceiling.)

CHAPTER 10 — Complaints and Product Recall

CHAPTER 11 — Self-Inspection

Cross-reference: NAFDAC GMP Guidelines 2024 vs. WHO GMP (TRS 961) vs. EU GMP (Vol. 4) vs. PIC/S status

Recommendation: extend this project's shared "Evidence Type" layer with two Nigeria-specific tags — ng_pharmacist_registration_credential (for the head-of-production Nigerian-pharmacist-licensure check, row 8) and per_container_api_identity_test (for the row-25 incoming-API check, given its uniquely well-documented failure consequence) — rather than folding either into the generic personnel_qualification_file or supplier_qualification_audit evidence types already used elsewhere in this project.

Gaps / follow-ups before this goes into production scoring

1. The legal-force status of the underlying "NAFDAC Good Manufacturing Practice for Pharmaceutical Products Regulations" is unverified and is the single biggest structural gap in this document. The 2024 Guidelines (this rubric's primary source) describe themselves as implementation guidance for a binding Regulations instrument, but the only document found under that title was a 2019 public-comment draft (60-day comment window ending 2 September 2019), fetched directly from NAFDAC's own site under a "DRAFT_REGULATIONS" folder path. Whether this specific draft was ever finalized/gazetted by the Governing Council and Minister of Health, superseded by a later draft, or remains formally unfinalized more than six years later, was not confirmed this session. Recommend a dedicated follow-up: search the Federal Republic of Nigeria Official Gazette (a gazetted Medical Devices Regulations 2024 was found at a Federal_Republic_of_Nigeria_Official_Gazette path this session, confirming NAFDAC does publish some regulations via official gazette — the equivalent pharmaceutical-GMP gazette entry, if one exists, was not located) before treating the Regulations (as opposed to the Guidelines implementing them) as confirmed current law.
2. No NAFDAC-published, English-language, aggregate GMP inspection-deficiency dataset was found, unlike the MHRA data underlying the companion gmp-gdp-rubric.md. Every failure-pattern cell above is a named case (with its category caveat) or a structural inference from the close NAFDAC/WHO/EU textual relationship — no clause here should be treated as empirically frequency-weighted. If Regscribe wants severity-weighting for NAFDAC GMP findings, rows 8 (Nigerian-pharmacist credential), 24–25 (supplier qualification / per-container API identity testing — the Barewa-precedent rows), and 35 (complaint counterfeit-vs-defect triage) are this session's reasoned high-consequence defaults, not citation-frequency-derived weights.
3. Chapter 9 (Contract Manufacturing and Analysis) is thin by the source document's own admission — it explicitly defers detail to "Guidelines For Contract Manufacturing Of Finished Pharmaceutical Products In Nigeria" (Doc. Ref. No. DER-GDL-023-00), which was not independently fetched this session. Recommend a follow-up fetch of that document before treating rows 33–34 as a complete picture of NAFDAC's contract-manufacturing expectations.
4. The API-specific GMP Guidelines (2025 Revised, adopting ICH Q7) were identified but not fetched/read to rubric depth this session — flagged in the scope-boundary note at the top of this document as a candidate future rubric (ng-nafdac-api-rubric.md or similar), analogous to how this project treats Japan's GQP/GVP Ordinances as separate candidate rubrics rather than folding them into the GMP Ordinance rubric.
5. PIC/S pre-applicant status is current only as of the 30 September 2025 PIC/S Secretariat announcement found this session — pre-accession processes can take years (PIC/S's own published multi-year timelines for other applicant countries were not independently checked this session), and Nigeria's status should be re-verified against picscheme.org's current applicant list before this rubric's PIC/S framing is treated as evergreen.
6. Only three named enforcement/quality-failure cases were researched to depth this session (Barewa/"My Pikin," EuroPharm/Eurolink, Benylin), against Nigeria's much larger and well-documented broader history of counterfeit/substandard-medicine incidents. This was a deliberate scope decision — this rubric's purpose is GMP gap-analysis of documents from facilities claiming GMP compliance, not counterfeit-detection — but a future session building a companion "Nigeria counterfeit/substandard medicine surveillance" reference (a different tool from this GMP rubric) would have a much larger body of source material to draw on (WHO Global Surveillance and Monitoring System reports, NAFDAC's own recurring Public Alerts archive).
7. The Chapter 3 clause-numbering defect (rows 11–13 cite "2.4x"/"2.5x" numbers under a "Chapter 3" heading) is a real property of NAFDAC's own published PDF, confirmed by direct inspection of the extracted text (not a rubric transcription error) — flagged prominently in Sources above so a future session doesn't "correct" the citations to a cleaner-looking "3.x" numbering that does not actually appear in the source document.